Filing Flows

Filing Flows › Companies › Nutex Health › Cash flow

Nutex Health cash flow, quarter by quarter

Latest: Q3 2026 · from the cash-flow statements filed with the SEC

Free cash flow$73.1M in Q3 2026 · $248M over twelve months

Operating cash flow$78.3M
Capital spending−$5.2M
Free cash flow+$73.1M
Cash / net income1.4×

Analysis

In Q3 2026, Nutex Health generated $78.3M of operating cash flow and spent $5.2M on capital projects, leaving free cash flow of $73.1M. That is $26.1M less than in Q3 2025 ($99.2M).

Over the twelve months to Sep 30, 2026, operating cash flow was $258M; the largest uses were other financing ($83.4M), buybacks ($55.7M), net borrowing (+) / repaid (−) ($18.1M); the cash balance rose by $87.2M.

Operating cash flow was $78.3M against net income of $57.3M — 1.4× profit, cash ran ahead of reported earnings. The largest differences: depreciation & amortization +$5.6M, prepaid and other assets +$3.8M, other liabilities +$2.7M.

Free cash flow

Nutex Health: free cash flow by quarterNutex Health: free cash flow by quarter−$341KQ4 2024$50.9MQ1 2025$26.5MQ2 2025$99.2MQ3 2025$69.0MQ4 2025$74.3MQ1 2026$31.7MQ2 2026$73.1MQ3 2026
Operating cash flow less capital spending.
Nutex Health: operating cash flow against capital spendingNutex Health: operating cash flow against capital spendingOperating cash flowCapital spending$54K$395KQ4 2024$51.0M$64KQ1 2025$27.3M$751KQ2 2025$99.5M$302KQ3 2025$70.4M$1.4MQ4 2025$75.5M$1.2MQ1 2026$34.2M$2.5MQ2 2026$78.3M$5.2MQ3 2026
Latest (Q3 2026): Operating cash flow $78.3M, Capital spending $5.2M.

Capital allocation, year by year

Nutex Health: where the cash came from (up) and went (down), by fiscal yearNutex Health: where the cash came from (up) and went (down), by fiscal yearOperating cash flowNet borrowingShares issuedCapital spendingAcquisitionsBuybacksFY2021: Operating cash flow $173MFY2021: Net borrowing −$3.0MFY2021: Shares issued $14.3MFY2021: Capital spending −$36.9M$188MFY2021FY2022: Operating cash flow $50.6MFY2022: Net borrowing −$891KFY2022: Shares issued $645KFY2022: Capital spending −$14.6M$51.3MFY2022FY2023: Operating cash flow $1.3MFY2023: Net borrowing −$1.3MFY2023: Capital spending −$9.5MFY2023: Acquisitions −$704K$1.3MFY2023FY2024: Operating cash flow $23.2MFY2024: Net borrowing −$9.1MFY2024: Shares issued $9.2MFY2024: Capital spending −$2.3M$32.4MFY2024FY2025: Operating cash flow $248MFY2025: Net borrowing −$19.4MFY2025: Capital spending −$2.5MFY2025: Buybacks −$5.0M$248MFY2025
Over these 5 years operating cash flow totalled $497M; the largest uses were capital spending ($65.9M) and net borrowing ($33.7M). Cash-flow statements as filed.

Cash runway and the debt wall

Cash & investments$250M
Debt$42.3M
Net cash$208M
Due within a year$14.1M

Nutex Health funds itself: free cash flow was $248M over the last twelve months, and $250M of cash and investments stands against $42.3M of debt ($14.1M due within a year, 17.8× covered by cash).

Nutex Health: debt maturities by year (FY2025)Nutex Health: debt maturities by year (FY2025)$14.1MYear 1$6.0MYear 2$3.4MYear 3$1.8MYear 4$8.7MYear 5$9.5MAfter year 5
Principal due in each year as disclosed in the annual report, against $250M of cash and investments now.

Where the cash came from and went

Nutex Health: sources (+) and uses (−) of cash, Q3 2026Nutex Health: sources (+) and uses (−) of cash, Q3 2026Operating cash flow$78.3MCash drawn (+) / kept (−)−$46.5MOther financing−$24.6MCapital spending−$5.2MNet borrowing (+) / repaid (−)−$2.1MBuybacks−$1K
Nutex Health: sources (+) and uses (−) of cash, TTM to Q3 2026Nutex Health: sources (+) and uses (−) of cash, TTM to Q3 2026Operating cash flow$258MCash drawn (+) / kept (−)−$87.2MOther financing−$83.4MBuybacks−$55.7MNet borrowing (+) / repaid (−)−$18.1MCapital spending−$10.4MOther investing−$3.7M

From profit to cash

Nutex Health: net income to operating cash flow, Q3 2026Nutex Health: net income to operating cash flow, Q3 2026Net income$57.3MDepreciation & amortization$5.6MDeferred taxes−$65KInventory−$937KPrepaid and other assets$3.8MOther liabilities$2.7MIncome taxes payable−$41KOperating cash flow$78.3M
Non-cash charges are added back; money tied up in receivables or inventory is subtracted.

Every quarter

QuarterOperating cash flowCapital spendingBuybacksNet borrowing (+) / repaid (−)Cash drawn (+) / kept (−)Free cash flow
Q3 2026$78.3M−$5.2M−$1K−$2.1M−$46.5M$73.1M
Q2 2026$34.2M−$2.5M−$19.0M−$3.2M$3.5M$31.7M
Q1 2026$75.5M−$1.2M−$31.7M−$3.7M−$24.8M$74.3M
Q4 2025$70.4M−$1.4M−$5.0M−$9.1M−$19.5M$69.0M
Q3 2025$99.5M−$302K—−$6.6M−$69.3M$99.2M
Q2 2025$27.3M−$751K—−$4.3M−$12.0M$26.5M
Q1 2025$51.0M−$64K—−$6.4M−$44.1M$50.9M
Q4 2024$54K−$395K—−$2.7M$6.3M−$341K

Nutex Health: income statement and cash flow

Nutex Health, Q3 2026: revenue $218M (-19% year over year), operating margin 35.4%. The chart follows the revenue to costs, profit and cash.

Nutex Health: every quarter, Q/Q and Y/Y → Open in the app

Read automatically from the company’s XBRL cash-flow statements; quarterly figures for the fourth quarter are the year less the first three. Errors are possible. Not investment advice.